ライフサイエンスコーパス: cholesterol-lowering

1 member 8 (ABCG8) did not associate with LDL cholesterol lowering.

2 sclerosis plaque regression after aggressive cholesterol lowering.

3 cardiovascular disease risk, despite plasma cholesterol lowering.

4 nriched functional foods are widely used for cholesterol lowering.

5 ct on statin-induced low-density lipoprotein cholesterol lowering.

6 dditional evidence of statin benefits beyond cholesterol lowering.

7 from intensive low-density lipoprotein (LDL)-cholesterol lowering.

8 nd enhances atherosclerosis regression after cholesterol lowering.

9 ipid levels alone, suggesting effects beyond cholesterol lowering.

10 suggesting that the effect is independent of cholesterol lowering.

11 Statins are first-line therapy drugs for cholesterol lowering.

12 ncreases monocyte entry into plaques despite cholesterol lowering.

13 erosclerosis-resolving M2 state typical with cholesterol lowering.

14 004) despite similar low-density lipoprotein cholesterol lowering.

15 ted with future coronary risk independent of cholesterol lowering.

16 Statins have different cholesterol lowering abilities, with rosuvastatin and at

17 The cholesterol-lowering abilities of rice bran's fiber and

18 the major phytocompounds responsible for the cholesterol lowering ability of apples.

19 works and provides a potential mechanism for cholesterol-lowering action of FGF19.

20 The cholesterol-lowering action of simvastatin was monitored

21 Despite well-known cholesterol-lowering action of statins, their mechanisms

22 fine the contributions of polyphenols to the cholesterol-lowering actions of lupins.

23 risk of AD, which has been attributed to the cholesterol-lowering actions of these drugs.

24 inflammatory actions are distinct from their cholesterol-lowering actions.

25 LOX-1 receptor is related to statin-mediated cholesterol-lowering activity is unknown.

26 ion, the present study demonstrates a marked cholesterol-lowering activity of proteins from L. angust

27 analogs that bind to NPC1L1 exhibit in vivo cholesterol-lowering activity, whereas compounds that do

28 f a key intermediate in the synthesis of the cholesterol lowering agent, atorvastatin.

29 mg, a more intensive low-density lipoprotein cholesterol lowering agent, reduced both first and subse

30 Consistently, the cholesterol-lowering agent (pravastatin sodium) downregu

31 e, the predicted systems pharmacology of the cholesterol-lowering agent ezetimibe corroborates its po

32 ments included aspirin use, treatment with a cholesterol-lowering agent, cardiac catheterization, and

33 Furthermore, treating zebrafish with a cholesterol-lowering agent, ezetimibe, reduced susceptib

34 CONTEXT: Atorvastatin calcium (ATV), a cholesterol-lowering agent, suffers from poor systemic a

35 s a probe to study HCV replication, and as a cholesterol-lowering agent.

36 nd 6 months after treatment with probucol, a cholesterol-lowering agent.

37 clerosis; however, additional or alternative cholesterol lowering agents are needed for patients who

38 in treatments for hypercholesterolemia with cholesterol lowering agents, cardiovascular disease stil

39 h as anti-infectives, antihypertensives, and cholesterol lowering agents.

40 ene cyclase inhibitors with high efficacy as cholesterol-lowering agents and of different chemical st

41 Investigational LDL cholesterol-lowering agents currently being tested in ca

42 Within just a few years, four new LDL-cholesterol-lowering agents have received regulatory app

43 Statins are widely used as cholesterol-lowering agents that also decrease inflammat

44 Statins are potent, cholesterol-lowering agents with newly appreciated, broa

45 ul (guggul) have been widely used in Asia as cholesterol-lowering agents, and their popularity is inc

46 Statins, extensively used as cholesterol-lowering agents, have recently been identifi

47 a potential target for novel antibiotics and cholesterol-lowering agents.

48 For these SNPs, the cholesterol-lowering allele consistently was associated

49 Exposures: Low-density lipoprotein cholesterol-lowering alleles in or near NPC1L1, HMGCR, P

50 es, to groups according to the number of LDL cholesterol-lowering alleles that they had inherited.

51 However, lovastatin (a cholesterol lowering and anti-inflammatory drug) adminis

52 herosclerotic plaques of diabetic mice after cholesterol lowering and may represent a novel approach

53 The TR beta subtype is involved in cholesterol lowering and possibly elevating metabolic ra

54 studies have suggested associations between cholesterol lowering and psychological well-being.

55 esis and serves as an alternative target for cholesterol-lowering and antibiotic drugs.

56 yocardial Ischemia Reduction with Aggressive Cholesterol Lowering) and PROVE-IT (Pravastatin or Atorv

57 ti-cancer, anti-hypertension, anti-diabetic, cholesterol-lowering, and cognition-improving.

58 years due to their health benefits, such as cholesterol lowering, anti-inflammatory, anti-atherogeni

59 g lifestyle factors, blood pressure control, cholesterol-lowering, antithrombotic therapy, and fixed-

60 The major determinant of cholesterol lowering appears to be nut dose rather than

61 Benefits of plant sterols (PS) for cholesterol lowering are compromised by large variabilit

62 The benefits of plant sterols (PSs) for cholesterol lowering are hampered by large heterogeneity

63 rticipants responding to PS consumption with cholesterol lowering better than the mean cholesterol lo

64 The cholesterol-lowering blockbuster drug pravastatin can be

65 lar function in diabetic mice independent of cholesterol lowering but via effects dependent on choles

66 ta, these data are the first to suggest that cholesterol lowering by pravastatin might increase the r

67 Furthermore, cholesterol lowering by statins, methyl-beta-cyclodextri

68 otective effects that are independent of LDL-cholesterol lowering called pleiotropic effects.

69 n found that some probiotic bacteria possess cholesterol-lowering capabilities.

70 Despite robust cholesterol lowering, cardiovascular disease risk remain

71 and-binding domain (LBD) in complex with the cholesterol-lowering compound SR12813 and a 25 amino aci

72 ked by the treatment of berberine, a natural cholesterol-lowering compound which functions as a HNF-1

73 SK9 expression by berberine (BBR), a natural cholesterol-lowering compound.

74 and suggests a possible therapeutic use for cholesterol lowering compounds in reducing Alternaria-st

75 asma membrane, suggests the possibility that cholesterol lowering compounds may be beneficial in alle

76 potential benefit of low-density lipoprotein cholesterol lowering could not be excluded.

77 We studied the effect on LDL cholesterol of cholesterol-lowering diets with varying amounts of lean

78 For rosuvastatin, a cholesterol-lowering drug and OATP1A/1B substrate, the l

79 e KRAS(G12D)-induced LCH-like mouse with the cholesterol-lowering drug atorvastatin ameliorated the p

80 metabolites in fungi, such as lovastatin, a cholesterol-lowering drug from Aspergillus terreus.

81 d not forget that niacin is an effective LDL-cholesterol-lowering drug in patients with high LDL leve

82 tal structures of hCE1 in complexes with the cholesterol-lowering drug mevastatin, the breast cancer

83 trials of cardiovascular outcomes of an LDL cholesterol-lowering drug recommended by the 2018 Americ

84 The cholesterol-lowering drug simvastatin promotes bone form

85 treatment of macrophages with lovastatin, a cholesterol-lowering drug that blocks farnesylation and

86 when the mice were treated with Ezetimibe, a cholesterol-lowering drug that blocks intestinal dietary

87 s statins, account for the great majority of cholesterol-lowering drug use.

88 Simvastatin is a cholesterol-lowering drug whose pleiotropic effects may

89 iation between statin use (vs. no use of any cholesterol-lowering drug) and the risk of having abnorm

90 cholesterol diet, with or without ezetimibe (cholesterol-lowering drug), and high-fat/high-cholestero

91 lytic process involved in the synthesis of a cholesterol-lowering drug, atorvastatin (Lipitor), and w

92 tin, a Food and Drug Administration-approved cholesterol-lowering drug, could protect against nigrost

93 n of Atorvastatin (AT) versus the non-statin cholesterol-lowering drug, Ezetimibe (EZT) on severity o

94 holesterol homeostasis and its response to a cholesterol-lowering drug, ezetimibe.

95 Similarly, pravastatin, another cholesterol-lowering drug, suppressed microglial inflamm

96 a decade after the approval of the last LDL-cholesterol-lowering drug, the cholesterol absorption in

97 Lovastatin, a clinically approved cholesterol-lowering drug, was used to modulate caveolae

98 le, was considered as a potential target for cholesterol-lowering drugs (the role that is now played

99 disease; and 44% and 50% taking statin-class cholesterol-lowering drugs and aspirin, respectively.

100 nd the development of the newly approved LDL-cholesterol-lowering drugs and critically review their e

101 coronary events in comparison to usual-care cholesterol-lowering drugs and whether perfusion changes

102 ssociated with increased AD risk, and use of cholesterol-lowering drugs associated with decreased ris

103 Current use of cholesterol-lowering drugs for five or more years was no

104 Statins were designed as cholesterol-lowering drugs for the prevention of coronar

105 antihyperglycaemic drugs and non-statin LDL-cholesterol-lowering drugs in patients with type 2 diabe

106 to oral hypoglycemic, antihypertensive, and cholesterol-lowering drugs into its Medicare Advantage q

107 bility to inhibit bunyaviruses with existing cholesterol-lowering drugs may offer new options for fut

108 Here, I propose that rather than being cholesterol-lowering drugs per se, statins act as vitami

109 the common chiral side chain of statin-type cholesterol-lowering drugs such as Lipitor (atorvastatin

110 s that could cause adverse drug reactions to cholesterol-lowering drugs such as statins.

111 Statins are widely prescribed cholesterol-lowering drugs that are a first-line treatme

112 Statins are well-established, cholesterol-lowering drugs that can reduce inflammation

113 Statins are cholesterol-lowering drugs that have been proven in rand

114 e A (HMG-CoA) reductase enzyme (statins) are cholesterol-lowering drugs that have shown promise as th

115 Statins are cholesterol-lowering drugs that inhibit 3-hydroxy-3-meth

116 Statins are effective cholesterol-lowering drugs that reduce the risk of cardi

117 Statins are widely used cholesterol-lowering drugs that selectively inhibit the

118 ls using non-physiological high fat diets or cholesterol-lowering drugs to modify plasma cholesterol,

119 acy of statins, the most prescribed class of cholesterol-lowering drugs used for the prevention and t

120 between high circulating cholesterol levels, cholesterol-lowering drugs, and breast cancer are confli

121 t studies have indicated statins, a class of cholesterol-lowering drugs, as a potential therapy for A

122 itors, which are the most commonly used oral cholesterol-lowering drugs, have immunomodulatory proper

123 Statins, cholesterol-lowering drugs, inhibit these deleterious pr

124 e relative risk for current users of general cholesterol-lowering drugs, mostly statins in this cohor

125 ned the association between long-term use of cholesterol-lowering drugs, predominantly statins, and t

126 late caveolin/caveolae expression, including cholesterol-lowering drugs, reversed the increased CCE a

127 ns with the 231 patients who did not use any cholesterol-lowering drugs, statin use was associated wi

128 The widely used cholesterol-lowering drugs, statins, were reported to re

129 Statins are cholesterol-lowering drugs, targeting HMG-CoA reductase,

130 cal pathway has given rise to a new class of cholesterol-lowering drugs, the proprotein convertase su

131 In the analysis of general cholesterol-lowering drugs, we ascertained 3420 cases of

132 hway and is inhibited by statins, a class of cholesterol-lowering drugs.

133 effects of rechallenge with statins or other cholesterol-lowering drugs.

134 utility of these fragments in the design of cholesterol-lowering drugs.

135 and cardiac events compared with usual-care cholesterol-lowering drugs.

136 Saponins have plasma cholesterol lowering effect in humans and are important

137 The cholesterol lowering effect of BAS may translate into a

138 n and oral bioavailability, and the greatest cholesterol-lowering effect in comparison with PB suspen

139 socalorically replaces SFA, the greatest LDL-cholesterol-lowering effect is seen with PUFA, followed

140 onal guidelines, increased the total and LDL cholesterol-lowering effect of a low-fat diet.

141 hesized that inflammation could diminish the cholesterol-lowering effect of a reduced-fat/low-cholest

142 This unexpected cholesterol-lowering effect of CXCR7 is beneficial for a

143 es probably underestimated the potential LDL cholesterol-lowering effect of diet.

144 Health claims regarding the cholesterol-lowering effect of soluble fiber from oat pr

145 ty in dialysis patients is likely due to the cholesterol-lowering effect of systemic inflammation and

146 with apple consumption, probably due to the cholesterol-lowering effect of the main bioactive compou

147 sterol and colorectal cancer risk suggests a cholesterol-lowering effect of undiagnosed malignancy.

148 Nuts have a cholesterol-lowering effect, but the relation between nu

149 fibre could be designed that yields the best cholesterol-lowering effect, using experiences in tailor

150 ct on diabetic neuropathy independent of its cholesterol-lowering effect.

151 ), and most of them demonstrated significant cholesterol lowering effects in a cholesterol-fed rat (C

152 Statins, in addition to their cholesterol lowering effects, can prevent isoprenylation

153 In addition to their cholesterol lowering effects, statins have pleiotropic a

154 In addition to the profound cholesterol-lowering effects of apheresis, other potenti

155 Furthermore, AAT3 augments LDL cholesterol-lowering effects of ApoB-ASO.

156 PCSK9 could be a novel mechanism behind the cholesterol-lowering effects of PUFAs.

157 andling without compromising the blood lipid/cholesterol-lowering effects of statins.

158 gests that this mechanism is involved in the cholesterol-lowering effects of the extract.

159 determine the state of the evidence for the cholesterol-lowering effects of three selected fibres an

160 lupus-like autoimmunity independent of their cholesterol-lowering effects via a shift from a Th1 to a

161 Besides their cholesterol-lowering effects, statins also possess broad

162 In addition to their cholesterol-lowering effects, statins inhibit cell proli

163 nic inflammation, in addition to their serum cholesterol-lowering effects, we hypothesized that stati

164 rest for new therapeutics with anticancer or cholesterol-lowering effects.

165 inal drug molsidomine, which may explain its cholesterol-lowering effects.

166 statins may be in part independent of their cholesterol-lowering effects.

167 ins appeared to be independent of the drugs' cholesterol-lowering effects.

168 In summary, this study demonstrates the cholesterol-lowering efficacy of short-term feeding of t

169 Results: Low-density lipoprotein cholesterol-lowering genetic variants at NPC1L1 were inv

170 statin with expected low-density lipoprotein cholesterol lowering >/= 50%) after adjustment for patie

171 The ability of cholesterol lowering HMG-CoA reductase inhibitors (stati

172 Orally administered cholesterol-lowering HMG-CoA reductase inhibitors (known

173 th cholesterol lowering better than the mean cholesterol lowering in all participants were 4.25 (95%

174 re well established as first-line agents for cholesterol lowering in cardiovascular disease, with acc

175 They also suggest cholesterol lowering in extra-hepatic tissues by statins

176 tus impairs atherosclerosis regression after cholesterol lowering in humans and mice.

177 that randomized clinical trials with remnant cholesterol lowering in individuals with high concentrat

178 The benefit of LDL cholesterol lowering in older patients was observed for

179 Intensive low-density lipoprotein cholesterol lowering in patients improved the rate of pl

180 These data support further LDL-cholesterol lowering in patients with cardiovascular dis

181 vention statin trials led to more widespread cholesterol lowering in patients with coronary disease a

182 of benefit and safety of more intensive LDL cholesterol lowering in patients with diabetes and estab

183 ynthesis, serves as an a priori predictor of cholesterol lowering in response to PS consumption.

184 Low-density lipoprotein (LDL) cholesterol lowering in response to PSs was associated w

185 therapies for low-density lipoprotein (LDL)-cholesterol lowering in the management of atheroscleroti

186 No study, however, has assessed benefits of cholesterol lowering in the primary prevention of corona

187 This study confirms the need for early cholesterol lowering in this high-risk population.

188 vailable agents may allow more effective LDL-cholesterol lowering in those patients intolerant of cur

189 rolonged half-life and increased duration of cholesterol lowering in two species in vivo by binding t

190 so as brain-protective, hepatoprotective and cholesterol lowering ingredients.

191 Plasma cholesterol lowering is beneficial in patients with athe

192 safely reduced, whether the mechanism of LDL-cholesterol lowering matters, and whether ever more aggr

193 Cholesterol lowering may also have beneficial effects in

194 7A1-rs3808607) T/T homozygotes showed no LDL cholesterol lowering (mean +/- SEM: -0.05 +/- 0.07 mmol/

195 Purpose Cholesterol-lowering medication (CLM) has been reported

196 Associations include use of cholesterol-lowering medication and intraretinal hyperre

197 Conclusion Cholesterol-lowering medication during adjuvant endocrin

198 When 32 men taking cholesterol-lowering medication were excluded, the inter

199 nhibitors have become the preferred class of cholesterol-lowering medication with an increasing body

200 a dietary supplement or if she needs to take cholesterol-lowering medication, and if so, whether she

201 s revealed that simvastatin, an FDA-approved cholesterol-lowering medication, inhibited STAT1 activat

202 ia (5.44-6.99 mmol/L) who were not receiving cholesterol-lowering medication.

203 l cholesterol level <200 mg/dL and no use of cholesterol-lowering medication; blood pressure 120/</=8

204 pertensive (41.1% vs 26.0%, P < 0.0001), and cholesterol-lowering medications (40.1% vs 27.8%, P = 0.

205 Of participants without changes in cholesterol-lowering medications (n = 114), plasma surro

206 he onion sign disproportionately were taking cholesterol-lowering medications (P=0.025).

207 the mevalonate pathway are major targets for cholesterol-lowering medications and anticancer drug dev

208 cholesterol determination or reported using cholesterol-lowering medications and who participated in

209 Although cholesterol-lowering medications can reduce the risk of

210 The increased use of cholesterol-lowering medications has apparently accounte

211 However, the age-adjusted use of cholesterol-lowering medications increased from 1.6% to

212 s antiplatelet, blood pressure-lowering, and cholesterol-lowering medications into a single pill asso

213 sociation was found for the use of nonstatin cholesterol-lowering medications or cyclooxygenase 2 inh

214 of changes in dietary fat intake and use of cholesterol-lowering medications to changes in concentra

215 The increased use of cholesterol-lowering medications was estimated to accoun

216 5.2 mmol/L (200 mg/dL) or who reported using cholesterol-lowering medications, 69.5% reported having

217 blood pressure, use of antihypertensive and cholesterol-lowering medications, smoking, total cholest

218 erol <5.17 mmol/L (<200 mg/dL) and not using cholesterol-lowering medications, systolic blood pressur

219 l cholesterol > or =200 mg/dL or who were on cholesterol-lowering medications, the proportion of men

220 Compared with participants not treated with cholesterol-lowering medications, those who were treated

221 f 2 and 4 egg yolks/d by older adults taking cholesterol-lowering medications.

222 icipants not using compared with those using cholesterol-lowering medications.

223 and quantified exposure to statins and other cholesterol-lowering medications.

224 e are confounded by postrandomization use of cholesterol-lowering medications.CVD risk in postmenopau

225 ocardial Ischaemia Reduction with Aggressive Cholesterol Lowering (MIRACL) C-reactive protein sub-stu

226 yocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) study.

227 yocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) study.

228 the Myocardial Ischemia Reduction With Acute Cholesterol Lowering (MIRACL) trial at baseline and afte

229 ntly transferred to monacolin J to yield the cholesterol-lowering natural product lovastatin.

230 h it is unclear whether this is secondary to cholesterol lowering or other mechanisms.

231 Despite aggressive low-density lipoprotein cholesterol lowering, patients continue to be at signifi

232 ought to investigate the associations of LDL cholesterol-lowering PCSK9 variants with type 2 diabetes

233 This suggests that cholesterol lowering per se has anti-inflammatory effect

234 , but whether this is due to pleiotropism or cholesterol lowering per se is unclear.

235 The cholesterol-lowering pharmaceutical gemfibrozil is a rel

236 It has also been suggested that the cholesterol-lowering potential of KJM may be greater tha

237 (1-->4)-beta-D-glucan), a dietary fibre with cholesterol lowering properties.

238 FR171456 is a natural product with cholesterol-lowering properties in animal models, but it

239 oducible assay useful for characterising the cholesterol-lowering properties of bioactive food compon

240 Cholesterol-lowering properties of phytosterols and phyt

241 These data suggest that non-cholesterol-lowering properties of statins may favorably

242 ists with beneficial low-density lipoprotein cholesterol-lowering properties that may provide additio

243 that soluble fibers, like pectin, had strong cholesterol-lowering properties that were beneficial in

244 In addition to their cholesterol-lowering properties, 3-hydroxy-3-methylgluta

245 Pu-erh tea displays cholesterol-lowering properties, but the underlying mech

246 ti-inflammatory effects independent of their cholesterol-lowering properties, which have been attribu

247 chemic cardiomyopathy independently of their cholesterol-lowering properties.

248 er of pathobiological processes beyond their cholesterol-lowering properties.

249 st cancer cells, which is independent of its cholesterol-lowering property.

250 e LDL cholesterol, and the evidence that LDL-cholesterol lowering reduces CVD incidence.

251 LDL cholesterol lowering significantly reduced the risk of m

252 Their combination with cholesterol-lowering statins elicits superior anti-tumor

253 ing and epithelial-mesenchymal transition by cholesterol-lowering statins may promote the basal type

254 rate-limiting enzyme Nsdhl or treatment with cholesterol-lowering statins switches glandular pancreat

255 ne compound, compactin, the precursor of all cholesterol-lowering statins, was of particular interest

256 s study population, most of whom were taking cholesterol-lowering statins.

257 erest for the production of natural dyes and cholesterol-lowering statins.

258 es risk of aggressive prostate cancer, while cholesterol lowering strategies may confer protective be

259 ned cholesterol's impact on human health and cholesterol-lowering strategies.

260 0002), whereas HS individuals failed to show cholesterol lowering (TC: -0.09 +/- 0.09 mmol/L; P = 0.2

261 We aimed to summarise the evidence of LDL cholesterol lowering therapies in older patients.

262 chanism, safety and efficacy of emerging LDL-cholesterol lowering therapies.

263 ption of proven effective therapies, such as cholesterol-lowering therapies and blood pressure manage

264 nal studies; however, randomized trials with cholesterol-lowering therapies in individuals with estab

265 Therefore, cholesterol-lowering therapies may induce dynamic and be

266 current efficacious low-density lipoprotein-cholesterol-lowering therapies.

267 standardize the background statin-based LDL cholesterol-lowering therapy and to establish participan

268 Residual confounding by cholesterol-lowering therapy and trans fat or limited va

269 lease niacin-laropiprant to statin-based LDL cholesterol-lowering therapy did not significantly reduc

270 hypercholesterolaemia who were on stable LDL cholesterol-lowering therapy for at least 4 weeks; all p

271 The target population for consideration of cholesterol-lowering therapy in a large, integrated heal

272 the use of intensive low-density lipoprotein cholesterol-lowering therapy in high-risk older persons

273 Cholesterol-lowering therapy leads to plaque stabilizati

274 f adults aged 40 to 65 years recommended for cholesterol-lowering therapy under each guideline were s

275 recommended for outcome-related benefits of cholesterol-lowering therapy.

276 of dialysis patients are better targets for cholesterol-lowering therapy.

277 chemia suggests that low-density lipoprotein cholesterol-lowering thresholds for ischemia and major a

278 Intensive LDL-cholesterol lowering to a mean of 79 mg/dl with atorvast

279 ization by 30%, compared with less intensive cholesterol-lowering to a mean of 101 mg/dl with atorvas

280 The clinical benefit of LDL cholesterol lowering treatment in older patients remains

281 in particular from early and more aggressive cholesterol-lowering treatment (eg, with PCSK9 inhibitor

282 monitoring patients who are receiving stable cholesterol-lowering treatment could be lengthened.

283 to individualized therapy for CKD patients: Cholesterol-lowering treatment for CKD patients with hig

284 Effective cholesterol-lowering treatment started in early childhoo

285 guideline instead proposes implementation of cholesterol-lowering treatment using evidenced-based int

286 The use of cholesterol-lowering treatment, angiography, and revascu

287 After 6 months of cholesterol-lowering treatment, only MR imaging measurem

288 describes key stages in the evolution of LDL cholesterol-lowering treatment.

289 fective statin-based low-density lipoprotein cholesterol-lowering treatment.

290 CL (Myocardial Ischemia Reduction with Acute Cholesterol Lowering) trial, respectively.

291 yocardial Ischemia Reduction With Aggressive Cholesterol Lowering) trial.

292 w-up of statin-based low-density lipoprotein cholesterol lowering trials improves the understanding o

293 We found that LDL cholesterol lowering was dispensable, but statin-induced

294 Low-density lipoprotein cholesterol lowering was less in subjects with higher (>

295 LDL cholesterol lowering was significantly greater with high

296 rculating lipid levels or statin-induced LDL-cholesterol lowering were tested for association with re

297 emonstrates significant and dose-related LDL cholesterol lowering with a PCSK9 monoclonal antibody in

298 rpose of this study was to determine whether cholesterol lowering with atorvastatin improves walking

299 ify individuals who would derive maximum LDL cholesterol lowering with PS consumption.

300 ts of the history of low-density lipoprotein-cholesterol lowering, with the discovery of the low-dens